Rozzano

• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M … Ended recruitment
  2023-507188-21-00 5 2021-04-20 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto … Ended recruitment
  2023-503916-33-00 5 2021-03-24 Diffuse Large B-Cell Lymphoma (DLBCL)
• A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact … Ended recruitment
  2022-502606-33-00 5 2021-02-26 Patients with histologically or cytologically documented non-squamous
• Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC Ended recruitment
  2024-512238-13-00 4 2021-02-10 Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer
• A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of son … Ended recruitment
  2024-516797-29-00 4 2021-01-12 locally advanced basal cell carcinoma
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk … Ended recruitment
  2023-507153-16-00 5 2020-11-18 Higher-Risk Myelodysplastic Syndrome
• This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in c … Ended recruitment
  2023-504491-15-00 1 2020-10-30 Human epidermal growth factor receptor (HER2)-Expressing Cancers
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended recruitment
  2024-514404-13-00 5 2020-10-01 Atopic Dermatitis
• A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended recruitment
  2023-506576-27-00 5 2020-09-30 EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
• Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended recruitment
  2023-507062-34-00 7 2020-08-07 High-Risk large B-Cell lymphoma
• Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Ended recruitment
  2024-512961-15-00 5 2020-08-05 Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
• CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi … Ended recruitment
  2023-509089-39-00 5 2020-07-01 Non-Muscle Invasive Bladder Cancer
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended recruitment
  2023-507419-37-00 5 2020-06-25 Plasma cell myeloma
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma and myxoid/round cell liposarcoma patients Ended recruitment
  2024-513032-14-00 4 2020-04-21 Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended recruitment
  2024-511653-22-00 5 2020-02-12 Cutaneous Squamous Cell Carcinoma (CSCC)
• A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral trea … Ended recruitment
  2024-511940-20-00 5 2020-02-05 Parkinson's disease
• Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC … Ended recruitment
  2023-508635-31-00 5 2019-12-03 Hepatocellular Carcinoma
• GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended recruitment
  2023-508526-10-00 7 2019-10-01 Malignant solid tumors: Patients with relapsed or refractory, advanced
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l … Ended recruitment
  2022-502616-37-00 9 2019-07-30 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
• Avelumab Program Rollover Study Ended recruitment
  2024-514274-46-00 5 2019-06-21 Solid Tumors

Showing 505–528 of 692 trials